Quinolines

Abstract

The present invention relates to 2-aminoquinolines of formula I wherein R 1 , R 2 and R 3 are as defined in the specification, as 5-HT 5A receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of CNS disorders.

1 . A compound of formula I 
     
       
         
         
             
             
         
       
     
     wherein
 R 1  is —NR a —Ar 1 , —NR b CH 2 —Ar 1 , —CH 2 NR b —Ar 1 , —NR c C(O)—Ar 1 , —OCH 2 —Ar 1 , —CH 2 O—Ar 1 , —CH 2 CH 2 —Ar 1 , —CH═CH—Ar 1 , —NHC(O)NH—Ar 1 , —NHSO 2 NH—Ar 1 , —NR c C(O)O—Ar 1 , —C(O)NR c CH 2 —Ar 1 , —CH 2 NR b CH 2 —Ar 1 , —NHC(═N—Ar 1 )—Ar 1 , —NR b CH 2 CH 2 CH 2 —Ar 1 , or —NR b CH 2 CH 2 O—Ar 1 , 
 R 2  is —Ar 1 , —CHR d —Ar 2 , or —CH 2 CH 2 O—Ar 2 , 
 R 3  is hydrogen,
 phenyl, or pyridinyl, optionally substituted with one or more C 1-4 -alkyl, halo, or C 1-4 -alkoxy, 
 —NR e R f , wherein R e  and R f  are each independently hydrogen, or 
 —(CH 2 ) m —OR g , wherein m is from 2 to 6, 
 
 Ar 1  and Ar 2  are each independently aryl or heteroaryl, each optionally substituted by one or more B, 
 B is C 1-7 -alkoxy,
 C 1-7 -haloalkoxy, 
 hydroxy, 
 halo, 
 C 1-7 -alkyl, optionally substituted with one or more halo, hydroxy, or cyano, 
 —S(O) 2 —C 1-7 -alkyl, 
 —NR i R ii , 
 —NR iii S(O) 2 R iv , 
 —NR iii C(O)R iv , 
 —C(O)NR iii R iv , 
 —S(O) 2 —NR iii R iv , 
 —CH 2 —O—R v , 
 —(OCH 2 CH 2 ) n —OR v , wherein n is from 1 to 3, 
 —CH 2 —(OCH 2 CH 2 ) n —OR v , wherein n is from 1 to 3, 
 —C(O)R v , 
 cyano, 
 nitro, 
 allyl, 
 C 3 - 7 -cycloalkyl, 
 5- to 7-membered monocyclic heterocycloalkyl, or 
 two residues B in ortho-position to each other form a 3- to 4-membered bridge of the formula —CH 2 CH 2 CH 2 —, —CH 2 CH 2 CH 2 CH 2 —, —O—C(R vi ) 2 —O—, —OCH 2 CH 2 O—, —OCH(R vii )CH(R viii )—, 
 
 R a , R b , R c , R d , and R g  are each independently hydrogen or C 1-7 -alkyl; 
 R i , R ii , R iii , R iv , and R v  are each independently hydrogen, C 1-7 -alkyl or —(CH 2 ) n —C 3-7 -cycloalkyl, wherein n is from 0 to 3; 
 R vi , R vii , and R viii  are each independently hydrogen, C 1-4 -alkyl or halogen; 
 or a pharmaceutically acceptable salt thereof. 
 
   
   
       2 . The compound of  claim 1 , wherein
 R 1  is —NR a —Ar 1 , —NR b CH 2 —Ar 1 , —CH 2 O—Ar 1 , —CH 2 CH 2 —Ar 1 , —CH═CH—Ar 1 , —NHC(O)NH—Ar 1 , —NHSO 2 NH—Ar 1 , or —NR c C(O)O—Ar 1 .   
   
   
       3 . The compound of  claim 2 , wherein
 R 1  is —NH—Ar 1 , —NHCH 2 —Ar 1 , —CH 2 O—Ar 1 , —CH 2 CH 2 —Ar 1 , —CH═CH—Ar 1 , —NHSO 2 NH—Ar 1 , or —NR c C(O)O—Ar 1 .   
   
   
       4 . The compound of  claim 1 , wherein
 Ar 1  and Ar 2  are each independently phenyl, naphthyl, aromatic 5- or 6-membered monocyclic heteroaryl or aromatic 9- or 10-membered bicyclic heteroaryl, wherein the aromatic 5- or 6-membered monocyclic heteroaryl or aromatic 9- or 10-membered bicyclic heteroaryl each contain one, two, three or four heteroatoms selected from N, O and S, the remaining ring atoms being C, and wherein each Ar 1  and Ar 2  is optionally and independently substituted by one or more B.   
   
   
       5 . The compound of  claim 4 , wherein
 Ar 1  and Ar 2  are each independently selected from the group selected from the group consisting of phenyl, naphthyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, tetrazolyl, indolyl, benzofuranyl, benzothiophenyl, benzimidazolyl, benzoxyzolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzotriazolyl, purinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phtalazinyl, or pteridinyl, each optionally substituted with one or more B.   
   
   
       6 . The compound of  claim 4 , wherein
 Ar 1  and Ar 2  are each independently selected from the group selected from the group consisting of phenyl, tetrazolyl, [1,3,4]-oxadiazolyl, [1,2,4]-oxadiazolyl, imidazolyl, oxazolyl, isoxazolyl, furanyl, pyridinyl, pyrimidinyl or benzoxazolyl, each optionally substituted with one of more B.   
   
   
       7 . The compound of  claim 1 , wherein
 R 2  is —CH 2 —Ar 2  or —CH 2 CH 2 O—Ar 2 .   
   
   
       8 . The compound of  claim 1 , wherein R 3  is hydrogen. 
   
   
       9 . The compound of  claim 1  wherein B is selected from the group consisting of
 C 1-7 -alkoxy,   C 1-7 -haloalkoxy,   halo,   C 1-7 -alkyl, optionally substituted with one or more halo, or hydroxy,   —CH 2 —O—R v ,   —(OCH 2 CH 2 ) n —OR v , wherein n is from 1 to 3,   —CH 2 —(OCH 2 CH 2 ) n —OR v , wherein n is from 1 to 3,   C 3 - 7 -cycloalkyl,   5- to 7-membered monocyclic heterocycloalkyl, preferably piperidinyl, and   two residues B in ortho-position to each other forming a —O—C(R vi ) 2 —O— bridge;   wherein R v  is as defined above, preferably R v  is methyl;   and wherein R vi  is as defined above, preferably R vi  is hydrogen.   
   
   
       10 . The compound of  claim 9 , wherein B is selected from the group consisting of
 C 1-7 -alkoxy,   C 1-7 -haloalkoxy,   halo,   C 1-7 -alkyl, optionally substituted with one or more halo, or hydroxy,   —CH 2 —O—R v ,   —(OCH 2 CH 2 ) n —OR v , wherein n is from 1 to 3,   —CH 2 —(OCH 2 CH 2 ) n —OR v , wherein n is from 1 to 3,   C 3-7 -cycloalkyl, and   piperidinyl;   wherein R v  is as defined above, preferably R v  is methyl.   
   
   
       11 . The compound of  claim 9 , wherein B is selected from the group consisting of
 C 1-7 -alkoxy,   halo,   C 1-7 -alkyl, optionally substituted with one or more halo, and   two residues B in ortho-position to each other forming a —O—C(R vi ) 2 —O— bridge,   wherein R vi  is as defined above, and preferably is hydrogen.   
   
   
       12 . The compound of  claim 1 , selected from the group consisting of
 N2-(2-phenoxy-ethyl)-N6-pyridin-3-ylmethyl-quinoline-2,6-diamine,   N2-(2-methoxy-benzyl)-N6-pyridin-3-ylmethyl-quinoline-2,6-diamine,   N6-benzyl-N2-(2-methoxy-benzyl)-quinoline-2,6-diamine,   N6-(2-methoxy-benzyl)-N2-(2-phenoxy-ethyl)-quinoline-2,6-diamine,   N6-(3-methoxy-benzyl)-N2-(2-phenoxy-ethyl)-quinoline-2,6-diamine,   N2-(2-methoxy-benzyl)-4-phenyl-N6-pyridin-3-ylmethyl-quinoline-2,6-diamine,   N2,N6-bis-(2-methoxy-benzyl)-quinoline-2,6-diamine,   N6-(3-methoxy-benzyl)-N2-(2-methoxy-benzyl)-quinoline-2,6-diamine,   N2-(2-methoxy-benzyl)-N6-(2-trifluoromethoxy-benzyl)-quinoline-2,6-diamine,   N6-(3-methoxy-benzyl)-N2-(2-methoxy-benzyl)-4-phenyl-quinoline-2,6-diamine, and   N2,N6-bis-(2-methoxy-benzyl)-4-phenyl-quinoline-2,6-diamine.   
   
   
       13 . The compound of  claim 1 , selected from the group consisting of
 N2-(5-methyl-furan-2-ylmethyl)-N6-pyridin-3-ylmethyl-quinoline-2,6-diamine,   N6-(2-methoxy-benzyl)-N2-(5-methyl-furan-2-ylmethyl)-quinoline-2,6-diamine,   N6-(3-methoxy-benzyl)-N2-(5-methyl-furan-2-ylmethyl)-quinoline-2,6-diamine,   N6-benzyl-N2-(5-methyl-furan-2-ylmethyl)-quinoline-2,6-diamine,   N-2-(4-fluoro-2-methoxy-benzyl)-4-phenyl-N-6-pyridin-3-ylmethyl-quinoline-2,6-diamine,   N2-(2-methoxy-benzyl)-N6-pyridin-3-ylmethyl-4-o-tolyl-quinoline-2,6-diamine,   N-2-(2-methoxy-benzyl)-4-(3-methoxy-phenyl)-N-6-pyridin-3-ylmethyl-quinoline-2,6-diamine,   4-(2,5-difluoro-phenyl)-N2-(2-methoxy-benzyl)-N6-pyridin-3-ylmethyl-quinoline-2,6-diamine,   N-6-benzyl-N-2-(4-fluoro-2-methoxy-benzyl)-4-phenyl-quinoline-2,6-diamine,   N-2-(4-fluoro-2-methoxy-benzyl)-4-phenyl-N-6-&-pyridin-4-ylmethyl-quinoline-2,6-diamine, and   N-6-2-benzyl-N-2-(4-fluoro-2-methoxy-benzyl)-4-o-tolyl-quinoline-2,6-diamine.   
   
   
       14 . The compound of  claim 1 , selected from the group consisting of
 N6-benzyl-N2-(4-fluoro-2-methoxy-benzyl)-quinoline-2,4,6-triamine,   N6-benzyl-N2-(2-methoxy-benzyl)-quinoline-2,4,6-triamine,   N2-(2-methoxy-benzyl)-N6-pyridin-3-ylmethyl-quinoline-2,4,6-triamine,   N2-(5-methyl-furan-2-ylmethyl)-N6-pyridin-3-ylmethyl-quinoline-2,4,6-triamine,   N6-benzyl-N2-(5-methyl-furan-2-ylmethyl)-quinoline-2,4,6-triamine,   N2-(3-methoxy-benzyl)-N6-pyridin-3-ylmethyl-quinoline-2,6-diamine,   N6-benzyl-N2-(5-fluoro-2-methoxy-benzyl)-quinoline-2,4,6-triamine,   N2-(5-fluoro-2-methoxy-benzyl)-N6-pyridin-3-ylmethyl-quinoline-2,4,6-triamine,   N2-benzo[1,3]dioxol-4-ylmethyl-N6-pyridin-3-ylmethyl-quinoline-2,6-diamine,   1-[2-(2-methoxy-benzylamino)-quinolin-6-yl]-3-(4-methoxy-phenyl)-urea, and   N-(4-fluorophenyl)-N′-{2-[(2-methoxybenzyl)amino]quinolin-6-yl}sulfamide.   
   
   
       15 . The compound of  claim 1 , selected from the group consisting of
 N6-(2-ethyl-2H-tetrazol-5-yl)-N2-(2-methoxy-benzyl)-quinoline-2,6-diamine,   N2-(2-methoxy-benzyl)-N6-(5-methyl-isoxazol-3-yl)-quinoline-2,6-diamine,   N2-(2-methoxy-benzyl)-N6-(4-methyl-pyrimidin-2-yl)-quinoline-2,6-diamine,   N2-(2-methoxy-benzyl)-N6-pyridin-2-yl-quinoline-2,6-diamine,   N2-(2-methoxy-benzyl)-N6-(4-trifluoromethyl-pyrimidin-2-yl)-quinoline-2,6-diamine,   N6-(5-cyclopropyl-[1,3,4]oxadiazol-2-yl)-N2-(2-methoxy-benzyl)-quinoline-2,6-diamine,   N2-(2-methoxy-benzyl)-N6-(6-trifluoromethyl-pyridin-2-yl)-quinoline-2,6-diamine,   2-{3-[2-(2-methoxy-benzylamino)-quinolin-6-ylamino]-phenyl}-ethanol, and   N2-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl)-N 6 -(6-methyl-pyridin-2-yl)-quinoline-2,6-diamine.   
   
   
       16 . The compound of  claim 1 , wherein
 R 1  is —NR a —Ar 1 , —NR b CH 2 —Ar 1 , —CH 2 O—Ar 1 , —CH 2 CH 2 —Ar 1 , —CH═CH—Ar 1 , —NHC(O)NH—Ar 1 , —NHSO 2 NH—Ar 1 , or —NR c C(O)O—Ar 1 .   R 2  is —Ar 2 , —CH 2 —Ar 2 , or —CH 2 CH 2 O—Ar 2 ,   R 3  is hydrogen, or
 phenyl or pyridinyl, optionally substituted with one or more C 1-4 -alkyl, halo, or 
   C 1-4 -alkoxy,   Ar 1  and Ar 2  are each independently phenyl, naphthyl, aromatic 5- or 6-membered monocyclic heteroaryl or aromatic 9- or 10-membered bicyclic heteroaryl, wherein each heteroaryl contains one, two, three or four heteroatoms selected from N, O and S, the remaining ring atoms being C, each Ar 1  and Ar 2  is optionally and independently substituted by one or more B,   B is C 1-7 -alkoxy,
 C 1-7 -haloalkoxy, 
 hydroxy, 
 halo, 
 C 1-7 -alkyl, optionally substituted with one or more halo, hydroxy, or cyano, 
 —S(O) 2 —C 1-7 -alkyl, 
 —NR i R ii , 
 —NR iii S(O) 2 R iv , 
 —N iii C(O)K iv , 
 —C(O)NR iii R iv , 
 —S(O) 2 —NR iii R iv , 
 —CH 2 —O—R v , 
 —(OCH 2 CH 2 ) n —OR v , wherein n is from 1 to 3, 
 —CH 2 —(OCH 2 CH 2 ) n —OR v , wherein n is from 1 to 3, 
 —C(O)R v , 
 cyano, 
 nitro, 
 allyl, 
 C 3 - 7 -cycloalkyl, 
 5- to 7-membered monocyclic heterocycloalkyl, or 
 two residues B in ortho-position to each other form a 3- to 4-membered bridge of the formula —CH 2 CH 2 CH 2 —, —CH 2 CH 2 CH 2 CH 2 —, —O—C(R vi ) 2 —O—, —OCH 2 CH 2 O—, —OCH(R vii )CH(R viii )—, 
   R a , R b , R c , and R g  are each independently hydrogen or C 1-7 -alkyl;   R i , R ii , R iii , R iv , and R v  are each independently hydrogen, C 1-7 -alkyl or —(CH 2 ) n —C 3-7 -cycloalkyl, wherein n is from 0 to 3;   R vi , R vii , and R viii  are each independently hydrogen, C 1-4 -alkyl or halogen;   or a pharmaceutically acceptable salt thereof.   
   
   
       17 . A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I 
     
       
         
         
             
             
         
       
     
     wherein
 R 1  is —NR a —Ar 1 , —NR b CH 2 —Ar 1 , —CH 2 NR b —Ar 1 , —NR c C(O)—Ar 1 , —OCH 2 —Ar 1 , —CH 2 O—Ar 1 , —CH 2 CH 2 —Ar 1 , —CH═CH—Ar 1 , —NHC(O)NH—Ar 1 , —NHSO 2 NH—Ar 1 , —NR c C(O)O—Ar 1 , —C(O)NR c CH 2 —Ar 1 , —CH 2 NR b CH 2 —Ar 1 , —NHC(═N—Ar 1 )—Ar 1 , —NR b CH 2 CH 2 CH 2 —Ar 1 , or —NR b CH 2 CH 2 O—Ar 1 , 
 R 2  is —Ar 2 , —CHR d —Ar 2 , or —CH 2 CH 2 O—Ar 2 , 
 R 3  is hydrogen,
 phenyl, or pyridinyl, optionally substituted with one or more C 1-4 -alkyl, halo, or C 1-4 -alkoxy, 
 —NR e R f , wherein R e  and R f  are each independently hydrogen, or 
 —(CH 2 ) m —OR g , wherein m is from 2 to 6, 
 
 Ar 1  and Ar 2  are each independently aryl or heteroaryl, each optionally substituted by one or more B,
 B is C 1-7 -alkoxy, 
 C 1-7 -haloalkoxy, 
 hydroxy, 
 halo, 
 C 1-7 -alkyl, optionally substituted with one or more halo, hydroxy, or cyano, 
 —S(O) 2 —C 1-7 -alkyl, 
 —NR i R ii , 
 —NR iii S(O) 2 R iv , 
 —NR iii C(O)R iv , 
 —C(O)NR iii R iv , 
 —S(O) 2 —NR iii R iv , 
 —CH 2 —O—R v , 
 —(OCH 2 CH 2 ) n —OR v , wherein n is from 1 to 3, 
 —CH 2 —(OCH 2 CH 2 ) n —OR v , wherein n is from 1 to 3, 
 —C(O)R v , 
 cyano, 
 nitro, 
 allyl, 
 C 3 - 7 -cycloalkyl, 
 5- to 7-membered monocyclic heterocycloalkyl, or 
 two residues B in ortho-position to each other form a 3- to 4-membered bridge of the formula —CH 2 CH 2 CH 2 —, —CH 2 CH 2 CH 2 CH 2 —, —O—C(R vi ) 2 —O—, —OCH 2 CH 2 O—, —OCH(R vii )CH(R viii )—, 
 
 R a , R b , R c , R d , and R g  are each independently hydrogen or C 1-7 -alkyl; 
 R i , R ii , R iii , R iv , and R v  are each independently hydrogen, C 1-7 -alkyl or —(CH 2 ) n —C 3-7 -cycloalkyl, wherein n is from 0 to 3; 
 R vi , R vii , and R viii  are each independently hydrogen, C 1-4 -alkyl or halogen; 
 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.